Literature DB >> 18718876

Performance of the BioPlex 2200 Autoimmune Vasculitis kit.

Ravi Kaul1, Kim Johnson, Heidi Scholz, Greg Marr.   

Abstract

The BioRad BioPlex 2200 Vasculitis kit demonstrates excellent relative sensitivity and relative specificity for the semi-quantitative detection of IgG autoantibodies to MPO, PR3 and GBM. The fully-automated platform simultaneously measures three analytes in a single tube, offering superior advantage in speed and ease of use over current assays. The availability of a fully-automated platform with 24-hour availability for these three antibodies may be of considerable value in the differential diagnosis of patients with rapidly progressive glomerulonephritis.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18718876     DOI: 10.1016/j.autrev.2008.07.033

Source DB:  PubMed          Journal:  Autoimmun Rev        ISSN: 1568-9972            Impact factor:   9.754


  9 in total

Review 1.  Laboratory investigation in the diagnosis of vasculitis.

Authors:  Luis Felipe Flores-Suárez
Journal:  Curr Rheumatol Rep       Date:  2009-12       Impact factor: 4.592

2.  Discrepancies between two immunoassays for the determination of MPO and PR3 autoantibodies.

Authors:  Qian Sun; Boris Calderon; Zhen Zhao
Journal:  Clin Chim Acta       Date:  2017-05-08       Impact factor: 3.786

3.  Advantages of multiplex proteomics in clinical immunology: the case of rheumatoid arthritis: novel IgXPLEX™: planar microarray diagnosis.

Authors:  Peter Lea; Edward Keystone; Sasi Mudumba; Anthony Kahama; Shi-Fa Ding; Jennifer Hansen; Azar A Azad; Sihe Wang; Deborah Weber
Journal:  Clin Rev Allergy Immunol       Date:  2011-08       Impact factor: 8.667

4.  Evaluation of the Bio-Rad BioPlex 2200 syphilis multiplex flow immunoassay for the detection of IgM- and IgG-class antitreponemal antibodies.

Authors:  E Gomez; D J Jespersen; J A Harring; M J Binnicker
Journal:  Clin Vaccine Immunol       Date:  2010-04-28

5.  Ischemic Stroke of Possible Embolic Etiology Associated With Nephrotic Syndrome.

Authors:  Claudie Roy; Yan Deschaintre; Ramsey Sabbagh; Daniel Roy; Héloïse Cardinal; Guillaume Bollée
Journal:  Kidney Int Rep       Date:  2017-04-21

Review 6.  Novel clinical and diagnostic aspects of antineutrophil cytoplasmic antibodies.

Authors:  Johannes Schulte-Pelkum; Antonella Radice; Gary L Norman; Marcos Lόpez Hoyos; Gabriella Lakos; Carol Buchner; Lucile Musset; Makoto Miyara; Laura Stinton; Michael Mahler
Journal:  J Immunol Res       Date:  2014-06-05       Impact factor: 4.818

7.  First steps in the standardization of immunoglobulin IgG myeloperoxidase-anti-neutrophil cytoplasmic antibody measurements.

Authors:  D P Hutu; E Tuddenham; E Monogioudi; P Meroni; H Schimmel; J Sheldon; I Zegers
Journal:  Clin Exp Immunol       Date:  2015-11-18       Impact factor: 4.330

Review 8.  Next-Generation Autoantibody Testing by Combination of Screening and Confirmation-the CytoBead® Technology.

Authors:  Mandy Sowa; Rico Hiemann; Peter Schierack; Dirk Reinhold; Karsten Conrad; Dirk Roggenbuck
Journal:  Clin Rev Allergy Immunol       Date:  2017-08       Impact factor: 8.667

9.  Clinical Utility of Serial Measurements of Antineutrophil Cytoplasmic Antibodies Targeting Proteinase 3 in ANCA-Associated Vasculitis.

Authors:  Gwen E Thompson; Lynn A Fussner; Amber M Hummel; Darrell R Schroeder; Francisco Silva; Melissa R Snyder; Carol A Langford; Peter A Merkel; Paul A Monach; Philip Seo; Robert F Spiera; E William St Clair; John H Stone; Ulrich Specks
Journal:  Front Immunol       Date:  2020-09-03       Impact factor: 7.561

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.